Roche Diagnostics Solutions at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Roche Diagnostics Solutions at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Roche Diagnostics Solutions San Diego, California	1 Director of Bioinformatics, SBX algorithm development
roche.com Subsidiary Roche sells NGS platforms, sequencing reagents and analysis software to research laboratories. Appointed Foundation Medicine CEO Dan Malarek to lead Diagnostics North America, bringing oncology-diagnostics experience to the role. › Appointed Foundation Medicine CEO Dan Malarek to lead Diagnostics North America, bringing oncology-diagnostics experience to the role. 2026-07 · source Globally launched AXELIOS 1, a next-generation sequencing platform built on its SBX technology, entering the competitive NGS instrument market. 2026-06 · source Agreed to acquire PathAI to add AI-driven pathology diagnostics, expanding its digital and computational diagnostics capabilities. 2026-05 · source Source: company newsroom H1 2026 Diagnostics sales CHF 6.7B, up 3% CER › Reported sales fell 3% in Swiss francs on currency; Roche confirmed its full-year outlook. · 2026-07-23 “The Diagnostics Division’s sales were +3% at CER, -3% when reported in CHF, to CHF 6.7 billion; We confirm our outlook.” Source: results release	Poster Wed Oct 21 2:30 pm Part of Omics Technologies Poster Wednesday Session Accurate detection of germline structural variants using duplex and simplex SBX Exhibit & Poster Hall · Board 8121W Artificial intelligenceBioinformaticsComputational toolsCopy number/structural variation

Organization

ASHG 2026 Attendance

San Diego, California

1 Director of Bioinformatics, SBX algorithm development

Subsidiary

Roche sells NGS platforms, sequencing reagents and analysis software to research laboratories.

Appointed Foundation Medicine CEO Dan Malarek to lead Diagnostics North America, bringing oncology-diagnostics experience to the role.

›

Appointed Foundation Medicine CEO Dan Malarek to lead Diagnostics North America, bringing oncology-diagnostics experience to the role.

2026-07 · source

Globally launched AXELIOS 1, a next-generation sequencing platform built on its SBX technology, entering the competitive NGS instrument market.

2026-06 · source

Agreed to acquire PathAI to add AI-driven pathology diagnostics, expanding its digital and computational diagnostics capabilities.

2026-05 · source

H1 2026 Diagnostics sales CHF 6.7B, up 3% CER

›

Reported sales fell 3% in Swiss francs on currency; Roche confirmed its full-year outlook. · 2026-07-23

“The Diagnostics Division’s sales were +3% at CER, -3% when reported in CHF, to CHF 6.7 billion; We confirm our outlook.”

Poster

Wed Oct 21
2:30 pm

Artificial intelligenceBioinformaticsComputational toolsCopy number/structural variation

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction